bevacizumab,panitumumab
amgen,roche,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
dr. yoshino, paradigm trial as the first plenary session abstract: pani + folfox vs bev + folfox as 1l ras wt mcrc. os in left-sided population, hr 0.82 (p=.031) #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.